NCT00828854 2022-06-30
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
Syndax Pharmaceuticals
Phase 2 Completed
Syndax Pharmaceuticals
GlaxoSmithKline
Novartis
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)